Considering the most popular anti-VEGF drug was within the top 5...

Considering the most popular anti-VEGF drug was within the top 5 of ALL drugs ranked by sales prior to patent expiration, that should give you a good idea of the potential addressable market. Best bit is that this doesn’t compete with these drugs, but works in harmony with them to boost efficacy, and most importantly, reverse the vision loss (not just temporarily pause it). The ASX has this company absurdly undervalued, treating it as if it is simply treating some rare disease when in fact AMD represents one of the biggest health related burdens for the government, and especially on society. 1 in 7 people over the age of 50 will get AMD, it affects everyone in one way or another and is a terribly debilitating condition. I have no intention of selling below $10, so either the market will eventually have to come to its senses or I guess I’ll be forced out due to a take over (although I can’t really see the company accepting a TO below $10 either)